Please try another search
Breaking News
For the nine months ended 31 March 2016, Pluristem Therapeutics Inc. revenues increased from $285K to $2.8M. Net loss decreased 12% to $17M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development expenses decrease of 5% to $16.4M (expense), Gain (loss) from derivatives and Fair v increase of 72% to $609K (income).
Period Ending: | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 |
---|---|---|---|---|
Total Revenue | 0.1 | 0.1 | 0.1 | 0.09 |
Gross Profit | 0.09 | 0.09 | 0.09 | 0.09 |
Operating Income | -7.53 | -6.3 | -5.62 | -6.71 |
Net Income | -7.23 | -6.25 | -5.91 | -6.2 |
Period Ending: | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 |
---|---|---|---|---|
Total Assets | 54.44 | 58.34 | 63.83 | 74.02 |
Total Liabilities | 8.88 | 9.2 | 10.13 | 11.9 |
Total Equity | 45.55 | 49.14 | 53.7 | 62.12 |
Period Ending: | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -15.59 | -9.03 | -3.46 | -19.12 |
Cash From Investing Activities | 18.67 | 10.72 | 4.52 | 1.98 |
Cash From Financing Activities | 1.36 | 0.77 | 0.11 | 12.62 |
Net Change in Cash | 4.45 | 2.47 | 1.17 | -4.51 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review